Molecular Biology of EBV in Relationship to HIV/AIDS-Associated Oncogenesis.
Acquired Immunodeficiency Syndrome
/ physiopathology
Carcinogenesis
Coinfection
/ virology
Epstein-Barr Virus Infections
/ physiopathology
HIV Infections
/ physiopathology
Herpesvirus 4, Human
/ physiology
Humans
Immunocompromised Host
Lymphoma, AIDS-Related
/ physiopathology
Neoplasms
/ physiopathology
EBV
HIV/AIDS
Latent infection
Lymphoma
Oncogenesis
Journal
Cancer treatment and research
ISSN: 0927-3042
Titre abrégé: Cancer Treat Res
Pays: United States
ID NLM: 8008541
Informations de publication
Date de publication:
Historique:
entrez:
8
12
2018
pubmed:
14
12
2018
medline:
27
6
2019
Statut:
ppublish
Résumé
Herpesvirus-induced disease is one of the most lethal factors which leads to high mortality in HIV/AIDS patients. EBV, also known as human herpesvirus 4, can transform naive B cells into immortalized cells in vitro through the regulation of cell cycle, cell proliferation, and apoptosis. EBV infection is associated with several lymphoma and epithelial cancers in humans, which occurs at a much higher rate in immune deficient individuals than in healthy people, demonstrating that the immune system plays a vital role in inhibiting EBV activities. EBV latency infection proteins can mimic suppression cytokines or upregulate PD-1 on B cells to repress the cytotoxic T cells response. Many malignancies, including Hodgkin Lymphoma and non-Hodgkin's lymphomas occur at a much higher frequency in EBV positive individuals than in EBV negative people during the development of HIV infection. Importantly, understanding EBV pathogenesis at the molecular level will aid the development of novel therapies for EBV-induced diseases in HIV/AIDS patients.
Identifiants
pubmed: 30523622
doi: 10.1007/978-3-030-03502-0_4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM